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Available online 25 March 2008The mitochondrial permeability transition pore (MPTP) plays a key role in cell death, especially necrosis, and
mediates the injury tissues such as the heart and brain experience following ischaemia and reperfusion.
However, the molecular identity of the MPTP remains uncertain. Knockout studies have conﬁrmed a role for
cyclophilin-D (CyP-D) in pore opening, probably mediated by its peptidyl–prolyl cis–trans isomerase activity
that facilitates a conformational change in an inner membrane protein. However, similar knockout studies
have cast doubt on the central role of the adenine nucleotide translocase (ANT), previously regarded as a
leading contender for the membrane component that forms the transmembrane channel of the MPTP. Here
we review the evidence for and against a role for the ANT inMPTP opening and conclude that it usually plays a
regulatory role rather than provide the transmembrane pore component. We suggest that the protein fulﬁlling
the latter role is the mitochondrial phosphate carrier (PiC) and summarise recent evidence in support of this
proposal. Our data are consistent with a model for the MPTP in which a calcium-triggered conformational
change of the PiC, facilitated by CyP-D, induces pore opening. We propose that this is enhanced by an
association of the PiC with the “c” conformation of the ANT. Agents that modulate pore opening may act on
either or both the PiC and the ANT.
© 2008 Elsevier B.V. All rights reserved.Keywords:
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The mitochondrial permeability transition pore (MPTP) is a non-
speciﬁc pore, permeable to all molecules of less than 1.5 kDa, which
opens in the inner mitochondrial membrane (IMM) under conditions
of calcium overload. Opening is greatly enhanced by adenine nucleo-
tide depletion, elevated phosphate and oxidative stress. These are
conditions known to accompany reperfusion following a period of
ischaemia, and in response to others stresses such as the application of
certain metabolic poisons and toxins. Indeed the opening of the MPTP
is now recognised to be a major cause of the necrotic cell death
occurring under such conditions (see [1–4]). The role, if any, of the
MPTP in healthy cells remains unclear since mice lacking cyclophilin-
D, a component of the MPTP, show know obvious phenotype other
than being protected against ischaemic injury [5–8].; BKA, bongkrekic acid; CAT,
lin; IMM, inner mitochondrial
pore; NEM, N-ethylmaleimide;
arrier; PPIase, peptidyl–prolyl
sanglifehrin A; VDAC, voltage
4 117 3312168.
trap).
ll rights reserved.1.1. The role of the MPTP in necrotic cell death
The role of theMPTP in necrotic cell death can be readily explained.
Once the pore opens it allows free passage of protons across the inner
membrane leading to a dissipation of the membrane potential and pH
gradient that comprise the proton motive force. Not only does this
prevent ATP generation by oxidative phosphorylation, but reversal of
the ATPase occurs causing the breakdown of cytosolic ATP generated
by glycolysis. As a result tissue ATP levels become severely compro-
mised and, left unchecked, thesewill lead tomajor perturbations in the
ionic and metabolic homeostasis of the cell. Ultimately these changes
will cause necrotic cell death through the activation of phospholipases,
nucleases and proteases [4,9,10]. Perhaps the best documented ex-
ample of the role of the MPTP in necrotic cell death is in reperfusion
injury of the heart [1,9], liver [11] and brain [12,13]. Here, the ischaemic
phase of the insult causes calcium concentrations to rise and the
production of some reactive oxygen species (ROS) that leads to oxi-
dative stress. Although ROS and calcium are potential triggers of MPTP
opening, the enhanced glycolysis that occurs during ischaemia leads to
accumulation of lactic acid and a decrease in intracellular pH. This
prevents MPTP opening which is progressively inhibited as the pH
drops below 7 [14]. However, upon reperfusion there is a burst of ROS
formation and the pH returns to normal, stimulating pore opening and
hence cell death [1,9].
The importance of theMPTP in the necrotic death of the heart, brain
and liver under such conditions was initially recognised through the
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(SfA) [15–18]. Furthermore, it is the hippocampus of the brain that is
most vulnerable to ischaemic and hypoglycaemic damage, and
mitochondria from this region are more susceptible to MPTP opening
in vitro than aremitochondria from the cortexor cerebellum [12,13,19].
Most recently, further proof of a critical role for MPTP opening in
necrotic cell death has been provided by the use of mice in which the
target of CsA and SfA, cyclophilin-D (CyP-D — see below) had been
knocked out. These animals showed substantial protection from
ischaemia/reperfusion damage (infarct size) of both the heart [6,7]
and brain [8]. In addition, the use of thesemice has shown that cardiac
failure associated with chronic calcium overload also involves MPTP-
dependent death of cardiac myocytes [20].
1.2. The role of the MPTP in apoptosis
Another consequence of MPTP opening is swelling of the mitochon-
drial matrix, and this may play a role in apoptotic cell death under some
conditions. Swellingoccurs because theMPTP is permeable to all solutes
of b1.5 kDa and once open the non-protein components of the mito-
chondrial matrix will rapidly equilibrate across the IMM. However, the
matrix proteins remain and because they are at a higher concentration
than in the cytosol, they will exert a colloidal osmotic pressure. It is this
that causes the matrix to swell, the folds of the cristae allowing this to
occur without breaking the IMM. However, the outermembrane cannot
accommodate much swelling of the matrix without the outer mem-
brane rupturing. Once such rupture occurs the contents of the inter
membrane space are released including cytochrome c and other pro-
apoptotic proteins such as Smac/Diablo and Apoptosis Inducing Factor
(AIF). Thus, even ifMPTPopening is insufﬁcient to depleteATP levels and
cause necrosis, apoptosis may result [4,4,10,21]. It should be noted,
however, that release of pro-apoptotic proteins from the inter mem-
brane space is normally mediated by speciﬁc permeabilisation of the
outer membrane through the action of pro-apoptotic members of the
Bcl-2 family such as Bax [22,23].
2. The molecular mechanism of the MPTP
In view of its critical role in cell death, it is clearly important to
understand the molecular mechanism of the MPTP. Several models
have been proposed and although there remains no consensus as to
the exact mechanism, there is increasing certainty that cyclophilin-D
(CyP-D) and the adenine nucleotide translocase (ANT) play important
roles. The remainder of this review will summarise the evidence for
their involvement and provide evidence that additional components
remain to be identiﬁed. We will brieﬂy outline evidence from our
laboratory that one such component may be the mitochondrial phos-
phate carrier (PiC).
2.1. The role of cyclophilin-D
A key to elucidating the mechanism of the MPTP was provided by
Crompton and colleagues who ﬁrst reported that sub-micromolar
concentrations of cyclosporin A (CsA) inhibit pore opening [24]. Studies
from this laboratory revealed that the potency of several CsA analogues
as inhibitors of the pore correlated with their ability to inhibit the
activity of a matrix peptidyl–prolyl cis–trans isomerase (PPIase) [25,26].
We subsequently puriﬁed this PPIase and identiﬁed it as cyclophilin-D
(CyP-D) [27]. CyP-D is a protein encoded by the PPIF gene of the nuclear
genome. It is synthesised in the cytosol and enters the mitochondria
using amitochondrial targeting sequencewhich is subsequently cleaved
off [28,29]. The importance of CyP-D has recently been conﬁrmed by the
demonstration that mitochondria from CyP-D knockout mice do not
exhibit CsA-sensitiveMPTP opening [6,7,30]. However, it is important to
note thatMPTPopening can still be demonstrated in thesemitochondria
if the calcium loading of the mitochondria is increased sufﬁciently. Thisis also the case for wild-type mitochondria that have been treated with
CsA [31]. These data support the hypothesis that pore opening involves a
conformational change in a membrane protein that is facilitated by the
PPIase activity of CyP-D but that can occur in the absence of CyP-D at
higher [Ca2+].
Cyclosporin A has some disadvantages as an inhibitor of CyP-D
since it forms a complex with cytosolic cyclophilin-A (CyP-A) that
inhibits the calcium activated proteinphosphatase calcineurin. Indeed,
it is through this pathway that the drug mediates its immunosuppres-
sive effects [32]. Thus when used in vivo CsA has the potential to exert
many other effects on cellular function independent of its inhibition
of MPTP opening (for examples see [33,34]). Consequently, several
CsA analogues have been developed that lack the ability to inhibit
calcineurin but which are still active as inhibitors of the PPIase activity
of CyP-D. These include 6-methyl-ala-CsA, 4-methyl-val-CsA (NIM-
811) and 3-D-methyl-ala-4-ethyl-val-CsA (DEBIO-025) [35–37]. In
addition we have shown that an unrelated immunosuppressant,
sanglifehrin A (SfA), is also a potent inhibitor of the PPIase activity of
CyP-D and inhibits the MPTP whilst being inactive against calcineurin,
[18]. However, SfA shows some differences from CsA in the way that
it inhibits MPTP opening. The concentration dependence of MPTP
inhibition by SfA is sigmoidal unlike CsA which shows a linear rela-
tionship [18]. Furthermore, SfA does not prevent CyP-D binding to the
inner membrane component of the MPTP whilst CsA inhibits binding.
Thus it would seem that SfA acts to inhibit MPTP opening by inhibiting
the conformation change catalysed by the bound CyP-D rather than by
CyP-D binding [18].
The data reviewed above established beyond doubt the role of
CyP-D in facilitating the opening of the MPTP. However, the identity
of the membrane protein that binds CyP-D is less certain. Indeed it is
possible that there is no speciﬁc protein involved and such a view
underlies the model for MPTP formation proposed by He and
Lemasters [38]. In this model it is proposed that the MPTP forms as
a result of the aggregation of misfolded integral membrane proteins
that have been damaged by oxidant and other stresses. CyP-D will
normally block conductance through these protein aggregates, but
when protein clusters exceed the CyP-D available to block con-
ductance, unregulated pore opening occurs that is stimulated by
calcium and inhibited by CsA binding to CyP-D. The apparent in-
volvement of the adenine nucleotide translocase (ANT) in pore
formation (see below) is explained in terms of the high amount of
this protein in the inner mitochondrial membrane and its suscept-
ibility to oxidative damage. Thus it is the protein most likely to form
aggregates. However, as outlined below, the activation and inhibi-
tion of MPTP opening by different ligands of the ANT that cause
opposite changes in its conformational state argues against such a
non-speciﬁc effect.
2.2. The adenine nucleotide translocase
2.2.1. Evidence for a role of the ANT in MPTP formation
The most widely accepted candidate for the membrane component
of theMPTP, ﬁrst proposed by us in 1990 [25], is the adenine nucleotide
translocase (ANT). The evidence for its involvement is considerable; it is
reviewed extensively elsewhere [39] andwill only be summarised here.
Early observations from several laboratories, includingour own, showed
that MPTP opening is enhanced by adenine nucleotide depletion and
inhibited by addition of ATP or ADP. Opening is alsomodulated by other
speciﬁc ligands of the ANT including carboxyatractyloside (CAT) and
bongkrekic acid (BKA). CAT induces the “c” conformation of the ANTand
sensitises pore opening to [Ca2+]. Conversely, BKA enhances the “m”
conformation” and inhibits pore opening [25,31,40,41]. In addition, the
ability of nucleotides to inhibit pore opening correlateswith their ability
to act as transportable substrates for the ANT [31].
More direct evidence that the ANT might bind CyP-D in a CsA-
sensitive manner was provided through the use of a CyP-D afﬁnity
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tathione sepharose support). Both we [42] and Crompton et al [43]
demonstrated that the ANT can bind to CyP-D, although in other
respects different conclusions were reached. In our own studies ANT
binding to CyP-D was found to be CsA-sensitive whilst Crompton et al
failed to detect CsA inhibition of binding. However, these workers
detected binding of the voltage dependent anion channel (VDAC) that
we did not observe. These differences may reﬂect the different deter-
gent solubilisation routine and our use of liver mitochondria rather
than the heart mitochondria used by Crompton et al.
We recently obtained further evidence for the speciﬁc binding of
CyP-D by the ANT using co-immunoprecipitation. For this purpose
the ANT from solubilised liver mitochondria was immunoprecipitated
using a polyclonal antibody against thewhole rat liver ANT, puriﬁed by
a published method [44]. Using this antibody, CyP-D was found to co-
immunoprecipitate with the ANT in a CsA-sensitivemanner whilst SfA
did not prevent the interaction [10]. These data are in agreement with
our earlier studies using GST-CyP-D pull-down [45]. Taken together,
accumulating data would seem to provide strong evidence for a CsA-
sensitive interaction between CyP-D and the ANT. However, very
recently we have established that the protein detected by the
polyclonal ANT antibody used in the immunoprecipitation experi-
ments is not actually the ANT but rather the mitochondrial phosphate
carrier (PiC). It appears that this must have been a contaminant in the
original puriﬁed rat liver ANT used to raise the antibody [46]. As we
discuss further below, we now believe that it is the PiC rather than the
ANT that is the major protein to bind CyP-D and form the MPTP.
Another strong line of evidence in favour of the involvement of the
ANT in MPTP opening comes from the ability of oxidative stress and
certain thiol reagents such as the vicinal thiol reagent phenylarsine
oxide (PAO) to stimulate MPTP opening. We have shown that such
treatments act by overcoming the ability of adenine nucleotides to
inhibit the MPTP [31]. Since the ANT from solubilised rat liver inner
mitochondrial membranes binds to immobilised-PAO, it was proposed
that this effect of PAO, and that of oxidative stress, was mediated by
cross-linking of vicinal thiols on the ANT [31]. Subsequent experi-
ments enables us to identify these thiol groups as Cys160 and Cys257 of
the ANT (numbering for rat ANT1), with modiﬁcation of Cys160 alone
by eosin-5-maleimide being sufﬁcient to overcome the MPTP in-
hibition by adenine nucleotides [45]. We have further suggested that
the well-established inhibition of MPTP opening by high membrane
potential [47] may reﬂect greater binding of adenine nucleotides to
thematrix surface of the ANT leading to a higher preponderance of the
“m” form of the ANT [31,39]. In contrast, we have proposed that the
inhibitory effect of low pH onMPTP opening [14] is probablymediated
by protons competing for Ca2+ at the calcium trigger site on the matrix
surface of the ANT [39].
The best circumstantial evidence that the ANT may contain this
trigger site for calcium comes from our demonstration that in
energised heart mitochondria sub-micromolar concentrations of
calcium induce the “c” conformation of the ANT, as does CAT, whilst
this effect is reversed by BKA or ADP which inhibit MPTP opening
[25,48,49]. Although the identity of this site has not been established,
there are several glutamate and aspartate residues on the inner
surface of the ANT that might bind calcium [39]. However, the recently
published three dimensional structure of the ANT in its CAT-bound
form [50] has not provided any further clues as to which, if any of
these residues may be involved. One feature that does emerge from
the published structure is that it has a large channel on the cytosolic
surface that penetrates deep into the membrane and is blocked by a
relatively narrow gate at the bottom. This would be consistent with
MPTP opening being mediated by a conformation change that wedges
this gate open.
The evidence presented so far is largely circumstantial and for a
deﬁnitive proof it would be necessary to show MPTP activity in a
reconstituted preparation of puriﬁed ANT. Although there have beenseveral reports of reconstitution of the MPTP from partially puriﬁed
solubilised inner membrane proteins that include the ANT and CyP-D,
and other reports of reconstitution using puriﬁed ANT and CyP-D, none
of these is very persuasive as reviewed elsewhere [39]. The most con-
vincing data comes from Brustovetsky and Klingenberg who used the
puriﬁed and reconstituted adenine nucleotide translocase ofNeurospora
crassa to demonstrate the formation of non-speciﬁc channels at high
calciumconcentrations [51]. Thesedata are consistentwith observations
from many laboratories that the MPTP can open at very high [Ca2+] in
CyP-D deﬁcient mitochondria [5–7,30] just as it can in control mito-
chondria treated with CsA [31]. The data are also consistent with the
proposal discussed above, that the effect of CyP-D is to facilitate the
pore-forming conformational change such that it occurs at lower [Ca2+].
Furthermore, subsequent experiments revealed that the opening prob-
ability of these pores at high membrane potential was increased by the
presence of cyclophilin fromN. crassa and by oxidative stress [52]. These
results might appear to conﬁrm that CyP-D can facilitate a calcium-
induced change in the conformation of the ANT that produces a channel,
and as suchmight appear to offer deﬁnitive proof of themodel. However,
aswe reviewbelow, recentdata cast doubton this. It should alsobenoted
that these experimentswere performedwith the ANT fromN. crassa and
it is not clear whether these mitochondria exhibit a conventional CsA-
sensitive MPTP since yeast mitochondria do not (see [39]).
2.2.2. Evidence against a role for the ANT in MPTP formation
Despite the strong evidence summarised above, an absolute re-
quirement for the ANT in MPTP formation has been ruled out by the
observation that mouse liver mitochondria lacking the two major
isoforms of ANT (ANT1 and ANT2) still exhibit a CsA-inhibitable MPTP,
although much higher calcium concentrations are required to initiate
pore opening [53]. We have expressed some concerns about these
data since export of mitochondrial ATP from the mitochondria to the
cytosol via the ANT is essential for many aspects of liver metabolism,
and especially urea synthesis and gluconeogenesis [54]. Yet thesemice
have no obvious disturbances of their liver metabolism. The explana-
tion for this may lie in published proteomic studies [55] which reveal
the presence of a novel ANT isoform, ANT4 [56], in mouse liver
mitochondrial inner membranes. It seems likely that it is this ANT4
that this is capable of maintaining sufﬁcient ATP/ADP transport to
support metabolism. Nevertheless, the data of Kokoszka et al cannot
be explained purely on the basis of such residual ANT being re-
sponsible for MPTP formation in these mitochondria since pore
opening was found to be insensitive to ligands of the ANT [53].
The ANT is the most abundant member by far of a large family of
mitochondrial carriers with common structural motifs [57], and one
explanation of the data of Kokoszka et al is that in its absence another
member of the family is capable of forming the MPTP [54]. An alter-
native explanation is that the ANT is not normally the major pore-
forming component of the MPTP, but rather plays only a regulatory
role [10]. Recently we have investigated the interaction between CAT
and PAO on MPTP opening and our new data provides further evi-
dence in support for this second possibility. Our previous studies had
demonstrated that the binding of the ANT to a PAO-afﬁnity matrix is
abolished by pre-treatment of mitochondria with CAT [31] and this is
consistent with the published structure of ANT1 with CAT bound. This
reveals that when CAT is bound Cys160 and Cys257 should be too far
apart to be cross-linked by PAO [50]. Thus it would be predicted that if
PAO was exerting its activation of MPTP opening purely by binding to
the ANT, no additional activation should be observed by PAO following
CAT treatment. Yet, as illustrated in Fig.1, this is not what we observed.
As we showed previously [31], CAT treatment greatly diminished the
sensitivity of the MPTP to inhibition by ADP, whilst an even greater
effect was observed following PAO treatment. This effect of PAO was
induced even in mitochondria pre-treated with CAT which stops the
ANT binding to a PAO-column. These data imply that PAOmust reduce
the ADP-sensitivity of the pore at least in part independently of its
Fig. 1. Phenylarsine oxide can activateMPTP opening in the presence of CAT.Mitochondria
were pre-swollen in the absence andpresenceof 5 μMCAT, 20 μMPAO, or both as indicated
and the sensitivity of MPTP opening to inhibition by ADP determined from the rate of
shrinkage (increase in A520) upon addition of the polyethylene glycol [31]. When present,
CATwas added 1minprior to addition of 20 μMPAO. The free [Ca2+]was set at 70 μM in the
assay buffer and [ADP] varied as shown. The inset shows the effect of CATon the binding of
theANT indetergent-solubilised rat liver innermitochondrialmembranes to immobilised-
PAO determined as described previously [31]. Data are taken from [46].
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involve the mitochondrial phosphate carrier (PiC).
2.3. The voltage dependent anion channel
Several other proteins have been proposed to be components of
the MPTP, including the voltage activated anion channel (VDAC, also
known as porin) and the peripheral benzodiazepine receptor (see
[4,9,23]). The possibility that these proteins might be involved was
originally proposed [58] because they co-purify as a complex with the
ANT under some conditions [59]. The same proteins are also thought
to interact at contact sites, points of intimate contact between theFig. 2. Identiﬁcation of inner mitochondrial membrane proteins that bind to a
phenylarsine oxide afﬁnity matrix. Inner mitochondrial membranes prepared from
control and CAT pre-treated beef heart mitochondria were solubilised in Triton X-100,
applied to the PAO-afﬁnity matrix and then eluted with dithiothreitol. Proteins were
separated by SDS/PAGE and revealed by Sypro-Ruby protein stain prior to iden-
tiﬁcation by mass spectrometry. From order of highest molecular weight these
proteins were ubiquinol–cytochrome c-reductase core protein II (UCRC-2); phosphate
carrier protein (PiC); adenylate kinase-2 (AK-2); NIPSNAP-2 (a protein of unknown
function). Data are taken from [46].inner and outer mitochondrial membranes [60]. Since that time the
groups of Kroemer and Brdiczka have suggested that other proteins
associated with the contact sites, such hexokinase, creatine kinase and
the anti- and pro-apoptotic proteins Bcl-2 and Bax may also be in-
volved in the regulation of the MPTP [61–64]. However, the evidence
that any of these components play an essential role in pore formation
(as opposed to a potential regulatory role) is weak.
Until recently, perhaps the strongest case could be made for an
involvementof VDAC inMPTP formation since Crompton and colleagues
had shown that both ANT and VDAC from detergent-solubilised heart
mitochondria could bind to GST-CyP-D [43], although our own data did
not conﬁrm this [42]. Subsequently, it was reported that the ability of
ubiquinone analogues such as UQ0 and Ro 68-3400 to inhibit MPTP
opening [65,66] was associated with labelling of a 32 kDa protein of the
inner mitochondrial membrane by [3H] Ro 68-3400, and this protein
was initially identiﬁed as VDAC1 [67]. However, it was later demon-
strated that Ro 68-3400 labels the same 32 kDa protein inmitochondria
lacking VDAC1, thus revealing that VDAC1 was not the target of ubi-
quinone analogues [68]. Furthermore, very recently it has been shown
that mitochondria lacking all isoforms of VDAC exhibit normal pore
opening, thus proving that VDAC is not an essential component of the
MPTP [69].
Our own very recent data [46] suggest that ubiquinone analogues
can bind to both the ANT, already implicated in the MPTP as noted
above, and the mitochondrial phosphate transporter (PiC) that we
now believe may also be involved in MPTP formation (see below).
Thus both UQ0 and Ro 68–3400 induce the “m” conformation of the
ANT and inhibit the mitochondrial phosphate transporter at similar
concentrations to those inhibiting the MPTP. Since both the ANT and
PiC proteins run on SDS-PAGE in the 30–34 kDa region, they represent
potential candidates for the protein labelled by [3H]-Ro 68–3400
[67,68].Fig. 3. Themitochondrial phosphate carrier rather than the ANT binds to CyP-D. In Panel
A, solubilised inner mitochondrial membranes prepared frommitochondria pre-treated
with 5 μMCsA or10 μMCATwere passed through a GST–CyP-D afﬁnity column and after
washing speciﬁcally bound proteins eluted with glutathione as described previously
[42,45]. Samples were separated by SDS/PAGE and analysed by Western blotting with
PiC and ANT antibodies. In Panel B, mitochondria were treated 2 μM CsA or 2 μM CAT
for 10 min, before their solubilisation and incubation with immunoprecipitating PiC
antibody. Immuno-complexes were separated by SDS/PAGE and analysed by Western
blotting with the antibodies indicated. Data are taken from [46].
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VDAC normally plays no role in MPTP formation, CyP-D deﬁnitely
plays a facilitating role in MPTP opening whilst the ANT plays some
role, probably regulatory, but is dispensable. However, we are still left
with the critical question as to what protein(s) normally form(s) the
inner membrane pore component of the MPTP. The data we describe
below suggest that the mitochondrial phosphate carrier (PiC) may
fulﬁl this role.
2.4. The mitochondrial phosphate carrier
Wenoted above that in the CAT-bound form theANTno longer binds
to a PAO-column, yet MPTP opening in CAT-treated mitochondria can
still be activated by PAO treatment (see also Fig.1). Thuswe investigated
what solubilised innermembrane proteins from CAT-treatedmitochon-
dria bind to a PAO-afﬁnity matrix [46]. We conﬁrmed that the major
protein of non-CAT-treated innermembranes to bind to thePAO-column
was the ANT but that four additional proteins were also bound (see
Fig. 2). Unlike the ANT, the binding of these proteins to the PAO-column
was uninﬂuenced by CAT treatment. Three of the proteins were in the
30–35 kDa region characteristic of mitochondrial membrane transpor-
ters andwere identiﬁed as NIPSNAP-2 (Swiss-Prot O75323), a protein of
unknown function also identiﬁed in mouse liver mitochondria [55]),
adenylate kinase 2 (AK2 — an intermembrane space enzyme) and the
mitochondrial phosphate carrier (PiC). The fourth protein band ran at
45 kDa and was identiﬁed as ubiquinol–cytochrome c-reductase core
protein II. Of these proteins the most likely candidates to play a role in
MPTP formation or regulationwould seem to be either AK-2, since it has
adenine nucleotide binding sites, or the PiC since phosphate has been
known as a potent activator of MPTP opening for many years [70].
However, AK-2 is a soluble protein and thus cannot be the membraneFig. 4. Scheme illustrating the proposed role of CyP-D, ANTand PiC in the formation of theMP
binding of the ANT in the “c” conformation to the PiC enhances pore formation. Some pore fo
compared to the PiC. The conformational change of the PiC (ANT) responsible for pore form
absence. Adenine nucleotides are proposed to inhibit by binding to the ANT and preventing i
suggested that PAO may modify cysteine residues on the ANT to prevent adenine nucleotide
pore-forming conformation.component of theMPTP. Furthermore, its involvement in regulationwas
eliminated by demonstrating that the potent inhibitor of adenylate
kinase, P1,P5-di(adenoside-5′) pentaphosphate had no effect on pore
opening at concentrations that inhibited AK2 activity by more than 90%
[46].
A role for the PiC is supported by the observation that mitochon-
drial phosphate transport can be inhibited by ubiquinone analogues
that inhibit pore opening (see above) and by N-ethylmaleimide (NEM)
[71], which is known to be a potent inhibitor of MPTP opening at low
concentrations [45,72]. Interestingly, Krämer and colleagues have
demonstrated that the PiC of yeastmitochondria can be converted into
a non-speciﬁc anion channel by dithiol cross-linking between two
Cys28 residueswithin transmembrane helix 1 to form a PiC dimer [73].
An equivalent cysteine residue (Cys27) is also present in mammalian
PiC and could account for the observed binding of the PiC to the PAO-
column that is CAT-insensitive (Fig. 2). It would also provide an ad-
ditional site of activation of the MPTP by PAO.
If the PiC acts as the pore-forming component of theMPTP it would
be predicted that it would bind CyP-D in a CsA-sensitive manner.
We have conﬁrmed this to be the case by both GST-CyP-D pull-down
experiments and co-immunoprecipitation [46]. Typical data are given
in Fig. 3. Furthermore, we were able to show that the ANT from CAT-
treated mitochondria also co-immunoprecipitated with the PiC, sug-
gesting the possibility that the MPTP might be formed as a complex
between the PiC, ANTand CyP-D. Indeed, there is evidence that the PiC
and ANTmay interact togetherwhen associatedwith the ATP synthase
within “the ATP synthasome” [74,75].
In addition to the data described above there is some circumstantial
evidence to support a critical role for the PiC in MPTP formation. It has
been observed that the knockdown of the PiC in HeLa cells reduces their
sensitivity to apoptosis induced by staurosporine [76] and others haveTP. The usual pore-forming component is proposed to be the PiC rather than the ANT, but
rmation by the ANT is not precluded but it is suggested that this is relatively ineffective
ation is facilitated by CyP-D binding in all cases, but can occur at high calcium in its
ts interactionwith the PiC and any pore formation it might undergo in its own right. It is
binding as well as directly modifying the PiC to increase its probability of entering the
951A.W.C. Leung, A.P. Halestrap / Biochimica et Biophysica Acta 1777 (2008) 946–952shown that the MPTP mediates apoptosis under these conditions [77].
Furthermore, PiC over expression in cells can induce apoptosis [76].
2.5. Conclusions — a new model for the MPTP
Ourdata lead us topropose amodel for theMPTP inwhich the pore-
forming component is the PiC rather than the ANT. This undergoes a
calcium-triggered conformational change to induce pore formation
which is facilitated by the peptidyl–prolyl cis–trans isomerase activity
of CyP-D. This allows for pore opening in the absence of CyP-D or the
presence of CsA but at a much higher calcium load as observed
[6,7,30,31]. An interaction of the PiC with the “c” conformation of the
ANT is proposed to enhance the sensitivity of the PiC to this con-
formational change, whereas the “m” conformationwould either exert
no such effect or inhibit the process. This would explain the ability to
demonstrate pore opening in mitochondria containing no ANT1 or
ANT2, but with reduced sensitivity to calcium and no sensitivity to
ligands of the ANT [53]. The activation of theMPTP by PAOmay involve
both a direct effect of PAO binding to the PiC and an additional effect to
prevent the adenine nucleotide inhibition mediated via the ANT.
Ubiquinone analogues and NEMmay work both by enhancing the “m”
conformation of the ANT and via binding to the PiC. Fig. 4 presents a
scheme summarising our new proposals.
In order to prove the role for the PiC in pore formation it will be
necessary to use siRNA knockdown or a transgenic mouse approach
using a conditional knockout. Such studies are underway. Further
proof of the involvement of both the PiC and ANT in the formation and
regulation of the MPTP could in principle be obtained through their
reconstitution into proteoliposomes and demonstration of calcium
mediated, CsA-sensitive pore opening. Work to this end is in progress,
but is hampered by the instability ofmitochondrialmembrane carriers
during puriﬁcation [39].
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